FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166483399> ?p ?o ?g. }

• W2166483399 endingPage "454" @default.
• W2166483399 startingPage "447" @default.
• W2166483399 abstract "Purpose The heterogeneity of diffuse large B-cell lymphoma (DLBCL) has prompted the search for new markers that can accurately separate prognostic risk groups. We previously showed in a multivariate model that LMO2 mRNA was a strong predictor of superior outcome in DLBCL patients. Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab. Patients and Methods DLBCL patients treated with anthracycline-based chemotherapy alone (263 patients) or with the addition of rituximab (80 patients) were studied using immunohistochemistry for LMO2 on tissue microarrays of original biopsies. Staining results were correlated with outcome. Results In anthracycline-treated patients, LMO2 protein expression was significantly correlated with improved overall survival (OS) and progression-free survival (PFS) in univariate analyses (OS, P = .018; PFS, P = .010) and was a significant predictor independent of the clinical International Prognostic Index (IPI) in multivariate analysis. Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. Conclusion We conclude that LMO2 protein expression is a prognostic marker in DLBCL patients treated with anthracycline-based regimens alone or in combination with rituximab. After further validation, immunohistologic analysis of LMO2 protein expression may become a practical assay for newly diagnosed DLBCL patients to optimize their clinical management." @default.
• W2166483399 created "2016-06-24" @default.
• W2166483399 creator A5001976357 @default.
• W2166483399 creator A5007154598 @default.
• W2166483399 creator A5008640997 @default.
• W2166483399 creator A5008961404 @default.
• W2166483399 creator A5013767912 @default.
• W2166483399 creator A5013781498 @default.
• W2166483399 creator A5022658681 @default.
• W2166483399 creator A5023194494 @default.
• W2166483399 creator A5026641386 @default.
• W2166483399 creator A5027080346 @default.
• W2166483399 creator A5027340494 @default.
• W2166483399 creator A5031758990 @default.
• W2166483399 creator A5036314999 @default.
• W2166483399 creator A5038555959 @default.
• W2166483399 creator A5049069261 @default.
• W2166483399 creator A5049160636 @default.
• W2166483399 creator A5058925624 @default.
• W2166483399 creator A5060176180 @default.
• W2166483399 creator A5070059120 @default.
• W2166483399 creator A5087847070 @default.
• W2166483399 date "2008-01-20" @default.
• W2166483399 modified "2023-10-16" @default.
• W2166483399 title "LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab" @default.
• W2166483399 cites W1912693401 @default.
• W2166483399 cites W1976564639 @default.
• W2166483399 cites W1980888760 @default.
• W2166483399 cites W1984632688 @default.
• W2166483399 cites W1988033413 @default.
• W2166483399 cites W1998275293 @default.
• W2166483399 cites W2022668368 @default.
• W2166483399 cites W2026688799 @default.
• W2166483399 cites W2028096444 @default.
• W2166483399 cites W2030277211 @default.
• W2166483399 cites W2031263707 @default.
• W2166483399 cites W2058015212 @default.
• W2166483399 cites W2064208261 @default.
• W2166483399 cites W2064597799 @default.
• W2166483399 cites W2075622521 @default.
• W2166483399 cites W2077832231 @default.
• W2166483399 cites W2078597493 @default.
• W2166483399 cites W2083773716 @default.
• W2166483399 cites W2092794436 @default.
• W2166483399 cites W2096008106 @default.
• W2166483399 cites W2121988260 @default.
• W2166483399 cites W2139954541 @default.
• W2166483399 cites W2140065103 @default.
• W2166483399 cites W2145304413 @default.
• W2166483399 cites W2147246240 @default.
• W2166483399 cites W2153230421 @default.
• W2166483399 cites W2153665789 @default.
• W2166483399 cites W2158267770 @default.
• W2166483399 cites W2160305510 @default.
• W2166483399 cites W2164134168 @default.
• W2166483399 cites W2169478074 @default.
• W2166483399 cites W3147894994 @default.
• W2166483399 doi "https://doi.org/10.1200/jco.2007.13.0690" @default.
• W2166483399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18086797" @default.
• W2166483399 hasPublicationYear "2008" @default.
• W2166483399 type Work @default.
• W2166483399 sameAs 2166483399 @default.
• W2166483399 citedByCount "160" @default.
• W2166483399 countsByYear W21664833992012 @default.
• W2166483399 countsByYear W21664833992013 @default.
• W2166483399 countsByYear W21664833992014 @default.
• W2166483399 countsByYear W21664833992015 @default.
• W2166483399 countsByYear W21664833992016 @default.
• W2166483399 countsByYear W21664833992017 @default.
• W2166483399 countsByYear W21664833992018 @default.
• W2166483399 countsByYear W21664833992019 @default.
• W2166483399 countsByYear W21664833992020 @default.
• W2166483399 countsByYear W21664833992021 @default.
• W2166483399 countsByYear W21664833992022 @default.
• W2166483399 countsByYear W21664833992023 @default.
• W2166483399 crossrefType "journal-article" @default.
• W2166483399 hasAuthorship W2166483399A5001976357 @default.
• W2166483399 hasAuthorship W2166483399A5007154598 @default.
• W2166483399 hasAuthorship W2166483399A5008640997 @default.
• W2166483399 hasAuthorship W2166483399A5008961404 @default.
• W2166483399 hasAuthorship W2166483399A5013767912 @default.
• W2166483399 hasAuthorship W2166483399A5013781498 @default.
• W2166483399 hasAuthorship W2166483399A5022658681 @default.
• W2166483399 hasAuthorship W2166483399A5023194494 @default.
• W2166483399 hasAuthorship W2166483399A5026641386 @default.
• W2166483399 hasAuthorship W2166483399A5027080346 @default.
• W2166483399 hasAuthorship W2166483399A5027340494 @default.
• W2166483399 hasAuthorship W2166483399A5031758990 @default.
• W2166483399 hasAuthorship W2166483399A5036314999 @default.
• W2166483399 hasAuthorship W2166483399A5038555959 @default.
• W2166483399 hasAuthorship W2166483399A5049069261 @default.
• W2166483399 hasAuthorship W2166483399A5049160636 @default.
• W2166483399 hasAuthorship W2166483399A5058925624 @default.
• W2166483399 hasAuthorship W2166483399A5060176180 @default.
• W2166483399 hasAuthorship W2166483399A5070059120 @default.
• W2166483399 hasAuthorship W2166483399A5087847070 @default.
• W2166483399 hasBestOaLocation W21664833991 @default.
• W2166483399 hasConcept C121608353 @default.

• next